Cytokinetics, Incorporated (CYTK)
Automate Your Wheel Strategy on CYTK
With Tiblio's Option Bot, you can configure your own wheel strategy including CYTK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CYTK
- Rev/Share 0.7269
- Book/Share -4.3433
- PB -15.6861
- Debt/Equity -1.9921
- CurrentRatio 6.8758
- ROIC -0.43
- MktCap 8105982790.0
- FreeCF/Share -3.7787
- PFCF -17.879
- PE -10.871
- Debt/Assets 0.7226
- DivYield 0
- ROE 2.3287
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | CYTK | Raymond James | -- | Market Perform | -- | -- | July 30, 2025 |
| Initiation | CYTK | Barclays | -- | Overweight | -- | $55 | April 24, 2025 |
| Initiation | CYTK | Citigroup | -- | Buy | -- | $86 | Feb. 7, 2025 |
| Initiation | CYTK | Stifel | -- | Buy | -- | $80 | Jan. 22, 2025 |
News
Cytokinetics Shareholder Alert By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - CYTK
Published: October 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK and NEW ORLEANS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company's securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Read More
Investors in Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights – CYTK
Published: October 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit.
Read More
Cytokinetics CEO: Advancing a next gen opportunity which could expand addressable market
Published: October 28, 2025 by: CNBC Television
Sentiment: Positive
Robert Blum, Cytokinetics CEO, joins 'Power Lunch' to discuss the company's value proposition, what the company is working towards and much more.
Read More
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CYTK
Published: October 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the “Class Period”), of the important November 17, 2025 lead plaintiff deadline.
Read More
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
Published: October 24, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 24, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the "Class Period"), of the important November 17, 2025 lead plaintiff deadline. So what: If you purchased Cytokinetics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
CYTK INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
Published: October 23, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you suffered losses in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) …
Read More
Deadline Alert: Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: October 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 17, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”).
Read More
Levi & Korsinsky Reminds Cytokinetics, Incorporated Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 17, 2025 - CYTK
Published: October 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cytokinetics investors who were adversely affected by alleged securities fraud between December 27, 2023 and May 6, 2025.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines – CYTK
Published: October 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate (“Cytokinetics” or the “Company”) (NASDAQ: CYTK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: October 17, 2025 by: PRNewsWire
Sentiment: Neutral
BENSALEM, Pa. , Oct. 17, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Read More
Deadline Alert: Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: October 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 17, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”).
Read More
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cytokinetics, Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: October 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) and certain of its officers.
Read More
Faruqi & Faruqi Reminds Cytokinetics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 17, 2025 - CYTK
Published: October 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options
Read More
CYTK SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
Published: October 15, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you suffered losses in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Oct. 15, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) …
Read More
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
Published: October 14, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 14, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the "Class Period"), of the important November 17, 2025 lead plaintiff deadline. So what: If you purchased Cytokinetics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CYTK
Published: October 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the “Class Period”), of the important November 17, 2025 lead plaintiff deadline.
Read More
Investors who lost money on Cytokinetics, Incorporated(CYTK) should contact Levi & Korsinsky about pending Class Action - CYTK
Published: October 10, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 10, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cytokinetics investors who were adversely affected by alleged securities fraud between December 27, 2023 and May 6, 2025.
Read More
Portnoy Law Firm Announces Class Action on Behalf of Cytokinetics, Incorporated. Investors
Published: October 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cytokinetics, Incorporated, (“Cytokinetics” or the "Company") (NASDAQ: CYTK) investors of a class action on behalf of investors that bought securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). Cytokinetics investors have until November 17, 2025 to file a lead plaintiff motion.
Read More
CYTK DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
Published: October 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options
Read More
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: October 03, 2025 by: PRNewsWire
Sentiment: Neutral
BENSALEM, Pa. , Oct. 3, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Read More
Portnoy Law Firm Announces Class Action on Behalf of Cytokinetics, Inc. Investors
Published: October 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 03, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cytokinetics, Inc., (“Cytokinetics” or the "Company") (NASDAQ: CYTK) investors of a class action on behalf of investors that bought securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). Cytokinetics investors have until November 17, 2025 to file a lead plaintiff motion.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines - CYTK
Published: October 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate ("Cytokinetics" or the "Company") (NASDAQ: CYTK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cytokinetics, Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: October 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) and certain of its officers.
Read More
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: October 01, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Oct. 1, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) have opportunity to lead the securities fraud class action lawsuit.
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options
Read More
Class Action Filed Against Cytokinetics, Incorporated (CYTK) - November 17, 2025 Deadline to Join - Contact Levi & Korsinsky
Published: September 26, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit.
Read More
Deadline Alert: Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: September 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 17, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”).
Read More
CYTOKINETICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Cytokinetics, Incorporated - CYTK
Published: September 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW ORLEANS, Sept. 25, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company's securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Read More
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cytokinetics, Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: September 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) and certain of its officers.
Read More
Faruqi & Faruqi Reminds Cytokinetics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 17, 2025 - CYTK
Published: September 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options
Read More
About Cytokinetics, Incorporated (CYTK)
- IPO Date 2004-04-30
- Website https://www.cytokinetics.com
- Industry Biotechnology
- CEO Robert I. Blum
- Employees 498